Menu Close

Welcome to ILC 2021!

Thank you for a successful ILC 2021!

Thank you for making the 2021 International Invasive Lobular Breast Cancer (ILC) Virtual Symposium a success.  Over 740 physicians, researchers, patient advocates, patients with ILC from 36 countries participated to learn about ILC and discuss the most current research underway to better understand this unique disease. 

The ILC Virtual Symposium was held June 24th-25th, 2021 with special ILC patient advocate focused sessions June 23rd and June 30th. The Symposium showcased rapid progress in lobular breast cancer research with an agenda that featured presentations and discussions tackling challenges and opportunities that are ongoing in ILC diagnostics, imaging, biology and treatment and the growth of patient advocacy organizations ready to support the research.

Speakers, supporting organizations, patient advocates and symposium participants shared enthusiasm to build international, collaborative research to better understand ILC and develop therapies for patients.  We look forward to following this symposium with concrete steps to build the essential tools for ILC research and launch the studies and trials that are needed to benefit patients.  We welcome your involvement moving forward.

Thank you to presenters and to our Symposium Sponsor, the Breast Cancer Research Foundation and our supporting organizations Susan G Komen, the European Lobular Breast Cancer Consortium, the Lobular Breast Cancer Alliance, Lobular Breast Cancer UK, Lobular Ireland and the Dynami Foundation whose support made this event possible. Thank you to the patients, survivors, patient advocates and breast cancer organizations who are a crucial part of research community in the fight against lobular breast cancer.

For those who missed the scientific or patient advocate focused sessions, recordings of presentations will become available over the next 1-2 weeks to watch and share.

We hope that the symposium sparked fresh ideas, inspiration, and new collaborations. We appreciate your attendance and participation, and we look forward to meeting again at an in-person Symposium in Europe in 2022.

Best Regards,

Virtual ILC Symposium Organizers

Watch the recorded sessions below

Thank you to the presenters who agreed to record and share their presentations.  Not all presentations were recorded. Please contact the presenters directly with questions.

ILC 2021 – Patient Advocate Orientation, June 23rd, 2021
Basic tools and information for patients and advocates to make the most of the scientific sessions of the International ILC Virtual Symposium and learn about lobular breast cancer. 

ILC 2021 – Scientific Sessions Day 1 – Morning, June 24th, 2021
Keynote Address: Christine Desmedt
Session 1: Addressing Challenges in Diagnosis, Pathology and Imaging

ILC 2021 – Scientific Sessions Day 1 – Afternoon, June 24th, 2021
Session 2: Addressing Challenges in ILC Treatment

ILC 2021 – Scientific Sessions Day 2 – Morning, June 25th, 2021
Panel Discussion: How researchers, clinicians and patient advocates can accelerate lobular breast cancer research
Session 1: New Avenues in ILC Research
 

ILC 2021 – Scientific Sessions Day 2 – Afternoon, June 25th, 2021
Session 2: Lobular Breast Cancer Biology

ILC 2021 – Symposium Highlights – June 30th, 2021
Highlights of the International ILC Virtual Symposium

Welcome to ILC 2021!

We are delighted to invite you to the International Invasive Lobular Breast Cancer (ILC) Virtual Symposium to be held virtually on June 24th-25th, 2021, with special patient advocate focused sessions June 23rd and June 30th. 

Registration is free and open to physicians, researchers, patient advocates and organizations interested in learning about ILC and the most current research to better understand this disease.  This virtual symposium replaces the 2020 symposium, canceled due to the pandemic.

We believe that this symposium will be an opportunity to share current research in ILC and continue to build a vibrant, collaborative community of physicians, researchers, and advocates, ultimately impacting outcomes for patients with ILC. We encourage you to participate in these discussions and to voice your ideas and suggestions as we plan future projects.

We take this opportunity to thank the patients, survivors, patient advocates and breast cancer organizations who are a crucial part of research community in the fight against lobular breast cancer. We hope that after the symposium you take away fresh ideas, inspiration, and new collaborations. We appreciate your attendance and participation in this symposium and we look forward to meeting again at an in-person Symposium in Europe in 2022.

Best Regards,

Steffi Oesterreich, PhD
Professor, Pharmacology & Chemical Biology, University of Pittsburgh
Co-Director of the Women’s Cancer Research Center
Co-Leader, Cancer Biology Program, UPMC Hillman Cancer Center
Magee-Womens Research Institute, Pittsburgh, PA
Co-Chair, International ILC Virtual Symposium

Otto Metzger, MD
Medical Oncologist, Dana-Farber Cancer Institute
Executive Officer, Alliance for Clinical Trials in Oncology
Harvard Medical School, Boston, MA
Co-Chair, International ILC Virtual Symposium

Christine Desmedt, PhD
Head of Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium
Co-Chair, International ILC Virtual Symposium


Patrick W.B. Derksen, PhD
Professor, University Medical Center (UMC) Utrecht, Utrecht, Netherlands
Co-Chair, International ILC Virtual Symposium




Sponsors

Supporters